Manufacturing GMP psychedelics for a world in need
Based in Princeton, British Columbia, Optimi Health functions as a true end-to-end producer and supplier of psychedelic medicines, offering formulation, active pharmaceutical ingredients (APIs), and drug product manufacturing from preclinical stages to analysis and commercial distribution.
Our in-house quality management systems include regular facility and process audits from our dedicated staff and third-party validation of all precursor materials, suppliers and end products to ensure the highest standard of quality and regulatory adherence
We are invested in providing the safest possible supply of synthetic and natural psychedelics to the international market.
We own 20,000 sq ft of state-of-the-art, technologically advanced manufacturing, cultivation and analytical facilities.
We research formulations and extraction methods and investigate molecular discovery with restricted psychedelic compounds.
We are invested in providing the safest supply of natural and synthetic psychedelics to the international market.
We own 20,000 sq ft of state-of-the-art, technologically advanced cultivation and analytical facilities.
We research formulations and extraction methods and investigate molecular discovery with restricted psychedelic compounds.
We’re building something amazing as the largest GMP-certified end-to-end producer of psychedelic compounds in North America. Our goal is to be the number-one trusted, compassionate supplier of safe psychedelic compounds in the world.
We are committed to being a top-tier ingredient supplier of safe, consistent pharmaceutical-grade psychedelic compounds.
Our ability to scale gives us the capacity to manufacture and develop psychedelics on demand while positioning our products at a reasonable market price.
We are creating a model where psychedelic medicines are accessible to all who need them.
We are committed to being a top-tier ingredient supplier of natural, pharmaceutical grade psilocybin and functional mushrooms.
We are creating a model where psilocybin and other psychedelic medicines are accessible to all who need them.
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th